The German biotech company Immatics Biotechnologies GmbH has become the latest European enterprise to list its shares on the US Nasdaq market in order to finance the development of immunotherapies for cancer. However Immatics chose an uncommon strategy for gaining market entry: it executed a reverse merger with a special purpose acquisition company.
